Effectiveness of Thrombopoietin-receptor Agonists in the Treatment of Refractory Immune Thrombocytopenia Associated to Systemic Lupus Erythematosus

REFERENCES

1. 1.↵
   1. Newman K,
   2. Owlia MB,
   3. Al-Hemaidi I,
   4. Akhtari M

   . Management of immune cytopenias in patients with systemic lupus erythematosus - old and new. Autoimmun Rev 2013;12:784–91.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Kuter DJ,
   2. Bussel JB,
   3. Newland A,
   4. Baker RI,
   5. Lyons RM,
   6. Wasser J,
   7. et al.

   Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013;161:411–23.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Rodeghiero F,
   2. Stasi R,
   3. Giagounidis A,
   4. Viallard JF,
   5. Godeau B,
   6. Pabinger I,
   7. et al.

   Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia (ITP): a pooled analysis of 13 clinical trials. Eur J Haematol 2013;91:423–36.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Bussel JB,
   2. Cheng G,
   3. Saleh MN,
   4. Psaila B,
   5. Kovaleva L,
   6. Medded B,
   7. et al.

   Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237–47.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Katsutani S,
   2. Tomiyama Y,
   3. Kimura A,
   4. Miyakawa Y,
   5. Okamoto S,
   6. Okoshi Y,
   7. et al.

   Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study. Int J Haematol 2013;98:323–30.

   OpenUrlCrossRef
6. 6.↵
   1. Gonzalez-Nieto JA,
   2. Martin-Suarez I,
   3. Quattrino S,
   4. Ortiz-Lopez E,
   5. Muñoz-Beamud FR,
   6. Colchero-Fernandez J,
   7. et al.

   The efficacy of romiplostim in the treatment of severe thrombocytopenia associated to Evans syndrome refractory to rituximab. Lupus 2011;20:1321–3.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Alkaabi JK,
   2. Alkindi S,
   3. Riyami NA,
   4. Zia F,
   5. Balla LM,
   6. Balla SM

   . Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus. Lupus 2012;21:1571–4.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Tomov S,
   2. Lazarchick J,
   3. Self SE,
   4. Bruner ET,
   5. Budisavljevic MN

   . Kidney-limited thrombotic microangiopathy in patients with SLE treated with romiplostim. Lupus 2013;22:504–9.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Cela I,
   2. Miller IJ,
   3. Katz RS,
   4. Rizman A,
   5. Shammo JM

   . Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus. Clin Adv Hematol Oncol 2010;8:806–9.

   OpenUrlPubMed
10. 10.↵
    1. Gudbrandsdottir S,
    2. Frederiksen H,
    3. Hasselbalch H

    . Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. Platelets 2012;23:423–9.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Thota S,
    2. Kistangari G,
    3. Daw H,
    4. Spiro T

    . Immune thrombocytopenia in adults: an update. Cleve Clin J Med 2012;79:641–50.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Kuwana K,
    2. Kaburaki J,
    3. Okazaki Y,
    4. Miyazaki H,
    5. Ikeda Y

    . Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology 2006;45:851–4.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Gernsheimer TB,
    2. George JN,
    3. Aledort LM,
    4. Tarantino MD,
    5. Sunkara U,
    6. Matthew Guo D,
    7. et al.

    Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost 2010; 8:1372–82.

    OpenUrlCrossRefPubMed